Clinical trials: Metastatic Colorectal Carcinoma
Head and Neck Cancer, Malignant Melanoma
GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors
The purpose of this study is to measure safety, tolerability, and preliminary antitumor efficacy of GM103 administered alone and in combination with pembrolizumab in patients with locally advanced, unresectable, refractory and/or…
- Conditions
- Head and Neck Cancer, Malignant Melanoma, Colorectal Cancer, Renal Cell Carcinoma
- Trial name
- NCT06265025
- Testing
- GM103 (Part A), GM103 (Part B), GM103 and Pembrolizumab (Part C)
- Where
- 4 sites in South Korea
- Volunteers
- 125 people
- Sponsor
- GeneMedicine Co., Ltd.
Colorectal Cancer
EDICT - Exercise inDuced Changes In Colorectal Cancer Tissues
This pilot study looks to explore the biological effects of exercise on cancer and muscle cells using a two week exercise program (HIThigh intensity training) on 20 patients with newly diagnosed and operable colorectal cancer…
- Trial name
- EDICT (NCT02056691)
- Testing
- Exercise programme, Muscle biopsy
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- The Royal Bournemouth Hospital
Lung Neoplasms, Neoplasm Metastasis
Mediastinal Lymph Node Dissection in Conjunction With Pulmonary Metastasectomy From Colorectal Cancer
To study whether or not total mediastinal lymph node dissection in conjunction with pulmonary metastasectomy from colorectal cancer is associated with improved survival compared to pulmonary metastasectomy only.
- Conditions
- Lung Neoplasms, Neoplasm Metastasis, Colorectal Cancer
- Trial name
- NCT03113318
- Testing
- Total mediastinal lymph node dissection and pulmonary metastasectomy, Only pulmonary metastasectomy
- Where
- Denmark
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Metastatic Colorectal Cancer
Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC
NIPIRESCUE evaluates nivolumab and ipilimumab in patients with MSI/dMMR mCRC resistant to anti-PD1 monotherapy and previously treated with fluoropyrimidine, oxaliplatine, irinotecan, and anti- vascular endothelial growth factor…
- Trial name
- NIPIRESCUE (NCT05310643)
- Testing
- Nivolumab, Ipilimumab
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer Metastatic
A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan
Primary Objective: To assess efficacy aflibercept + 5-fluorouracil (5-FU)/levofolinate/irinotecan (FOLFIRI) by objective response rate (ORR).
- Trial name
- NCT01882868
- Testing
- Aflibercept, Levofolinate, Irinotecan
- Where
- 19 sites in Japan
- Volunteers
- 62 people
- Sponsor
- Sanofi
Metastatic Colorectal Cancer
Chidamide + Celecoxib in Advanced Metastatic Colorectal Cancer (CCmCC)
This study is designed as an open-label, dose-escalation manner to determine the MFD of chidamide in combination with celecoxib in patients with advanced mCRC.
- Trial name
- NCT05281276
- Testing
- chidamide, celecoxib
- Where
- Taiwan
- Volunteers
- 9 people
- Sponsor
- Taipei Medical University Shuang Ho Hospital
Colorectal Cancer
Biomarker Analysis in Metastatic Colorectal Cancer Treated With Cetuximab
Prometheus's Onco dX assay platform provides technological breakthrough for immunoassay by obtaining a level of sensitivity down to single tumor cells without compromising specificity.
- Trial name
- NCT02029326
- Where
- South Korea
- Volunteers
- 30 people
- Sponsor
- Samsung Medical Center
Metastatic Colorectal Cancer (CRC)
NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer
To explore the safety and efficacy of NALIRIFOX plus targeted therapy versus FOLFOX plus targeted therapy as first-line treatment for metastatic colorectal cancer.
- Trial name
- NCT07309289
- Testing
- NALIRIFOX plus targeted therapy, FOLFOX plus targeted therapy
- Where
- China
- Volunteers
- 144 people
- Sponsor
- Shanghai Zhongshan Hospital
Colorectal Cancer
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
RAS mutations are found in nearly half of colorectal cancer patients. However, except for G12C mutation, no driven gene targeted drug can be used.
- Trial name
- NCT05842525
- Testing
- intensive treatment, Maintenance treatment
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Hunan Cancer Hospital
Metastatic Colorectal Cancer
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
The combination of capecitabine and cetuximab as first-line therapy will result in improved progression free survival compared to single agent capecitabine in patients with KRAS wild type colorectal cancer.
- Trial name
- NCT00954876
- Testing
- capecitabine and cetuximab
- Where
- United States
- Sponsor
- Translational Genomics Research Institute
Metastatic Colorectal Cancer
SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum…
- Trial name
- NCT01966289
- Testing
- CY, GVAX, SGI-110
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Advanced Breast Cancer, Advanced Colorectal Cancer
Rehabilitation for People With Advanced Cancer
The proposed study is a Phase II, feasibility, randomized controlled preference based study. This will be conducted in Vancouver and Toronto and includes breast and colorectal cancers.
- Conditions
- Advanced Breast Cancer, Advanced Colorectal Cancer, Cancer Rehabilitation
- Trial name
- NCT05424068
- Testing
- In-person rehabilitaiton group, Virtual rehabilitation group
- Where
- Canada
- Volunteers
- 111 people
- Sponsor
- University Health Network, Toronto
Colorectal Cancer
Study of FOLFIRI Plus Bevacizumab in Colorectal Cancer Patients
Objectives: 1. To estimate progression-free survival (PFS) at 12 months in subjects with metastatic colorectal cancer who receive FOLFIRI [folinic acid (leucovorin or LV), 5-Fluorouracil (5-FU), irinotecan) plus bevacizumab as…
- Trial name
- NCT00354978
- Testing
- 5-Fluorouracil, Bevacizumab, Leucovorin
- Where
- 2 sites in United States
- Volunteers
- 49 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Cancer, Melanoma
Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors
This is a pilot study designed to evaluate the cutaneous effect of systemic inhibition of the tyrosine kinase pathway in the presence or absence of solar simulated light exposure.
- Conditions
- Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer
- Trial name
- NCT03176485
- Testing
- Solar Simulator
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Arizona
Colorectal Cancer Metastatic, Mismatch Repair Deficiency
The mCRC Patients With pMMR/MSS or dMMR/MSI-H Status Received Palliative Chemotherapy Efficacy and Survival
Deficient mismatch repair (dMMR) or microsatellite instability high (MSI-H) accounts for 4-5% in metastatic colorectal cancer (mCRC).
- Conditions
- Colorectal Cancer Metastatic, Mismatch Repair Deficiency, Microsatellite Instability High
- Trial name
- NCT04482608
- Where
- China
- Volunteers
- 671 people
- Sponsor
- Sun Yat-sen University
Advanced Solid Tumors, Genital Neoplasm, Female
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
This is an open label, multicenter, phase 1/2 study to assess the safety/tolerability and preliminary clinical activity of STAR0602 as a single agent and in combination with chemotherapy administered intravenously in participants…
- Conditions
- Advanced Solid Tumors, Genital Neoplasm, Female, Urogenital Neoplasms, Lung Neoplasm
- Trial name
- START-001 (NCT05592626)
- Testing
- STAR0602, Irinotecan (Camptosar), Docetaxel (Taxotere)
- Where
- 19 sites in United States, Canada and 2 more
- Volunteers
- 366 people
- Sponsor
- Marengo Therapeutics, Inc.
Metastatic Colorectal Cancer
A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment
A post marketing surveillance, prospective study to collect safety information from 250 subjects with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer treated with Erbitux as final…
- Trial name
- NCT01134640
- Where
- 15 sites in Taiwan
- Volunteers
- 286 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
EGFR-positive Colorectal Cancer
EGFR CART Cells for Patients With Metastatic Colorectal Cancer
This is a clinical study to observe the maximum tolerated dose (MTD) and the safety and feasibility of chimeric antigen receptor EGFR (EGFR CART) cells in metastatic patients with colorectal cancer.
- Trial name
- NCT03152435
- Testing
- EGFR CART
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Second People's Hospital
BRAF V600E-mutant Metastatic Colorectal Cancer
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer
This trial aims to elucidate the immune landscape and genetic basis of BRAF-mutant colorectal cancer (CRC) in Chinese patients by analyzing tumor tissue and peripheral blood.
- Trial name
- NCT07007689
- Volunteers
- 200 people
- Sponsor
- Sun Yat-sen University
Metastatic Colorectal Cancer, BRAF V600 Mutation
A Study on Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC)
Previous studies have shown that BRAFV600E mutant mCRC patients have a shorter survival time than BRAF wild type mCRC patients. For Chinese patients, however, it remains unclear about the BRAF gene mutation rate, diagnosis…
- Trial name
- NCT06749015
- Testing
- Non interventional study
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Fudan University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.